List of reimbursed medicines expanded

Chisinau, 25 January /MOLDPRES/- The list of reimbursed medicines of the compulsory health insurance funds was filled in with six new names, indicated in the treatment of 10 diseases.

According to the National Health Insurance Company, three drugs will be fully compensated. These include deflazacortum for the treatment of autoimmune diseases, including rheumatoid arthritis, rare diseases such as bullous epidermolysis, muscular dystrophy. The other two are: levetiracetamum for the treatment of epilepsy, as well as an innovative drug, aripiprazolum, prescribed to children up to 18 years of age in case of schizophrenia.

Patients will receive a compensation of 70% of the price for cabergolinum, prescribed for hyperprolactinemia - a condition characterized by high blood levels of a hormone called prolactin. At the same time, deflazacortum will be indicated in the treatment of asthma, being compensated in a proportion of 70% for adults and 100% for children up to 18 years.

Two other preparations will have a compensation rate of 30%. These include memantinum, a drug used to treat Alzheimer's disease, and rosuvastatin for the treatment of cardiovascular diseases associated with dyslepidemia.

In 2021, over 678 million lei was planned in the compulsory health insurance funds for compensated pharmaceutical preparations. Currently, the list of reimbursed medicines includes 158 international common names and can be found at the family doctor, in pharmacies or on the CNAM website.

photo: msmps.gov.md